Project Name: Nottingham GP Alliance Lipid Optimisation Collaborative Working Project
Project Summary:
The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (“ASCVD”) who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner.
The CWP will be led by a Chief Pharmacist alongside a multi-disciplinary team; including Lead Clinical Pharmacist, General Practitioner, Healthcare Assistant and Care Coordinators, aiming to achieve:
- Identification of sub-optimally treated ASCVD patients who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidelines
- Identification of ASCVD patients who are at higher risk of cardiovascular events and who have previously not tolerated or refused alternative lipid modification therapies
- Review of treatment options and decision on next steps in collaboration with ASCVD patients
- Counsel and optimise ASCVD patients where appropriate
- Early identification of at-risk patients who have not had intervention in their health and wellbeing
- Identification of ASCVD patients, following risk assessment review, of ASCVD patients who are sub-optimally treated
- On-going ASCVD patients support and annual review to ensure CVD outcomes improve equitably
- Upskilling of existing workforce within the GP Alliance
Planned Milestones:
- Collection of baseline data, in line with the Project Outcome Measures & Data Collection table
- Lipid Management pathway/protocol development
- PCN Engagement and training plan
- Collection of 3 months clinical activity data & Project Review meeting to discuss project progress.
- Collection of 6 months clinical activity data & Project Review meeting to discuss project progress.
- Collection of 9 months clinical activity data & Project Review meeting to discuss project progress
- Collection of 12 months clinical activity data & Project Review meeting to discuss project progress
- Development of business case
- Analysis of CWP data, submission of Final CWP Report, Submission of Outcomes Summary
Expected Benefits:
Anticipated Benefits for Patients:
- Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
- Enhanced experience around ASCVD with ongoing management of the condition.
- Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events
- Easier access to lipid management care closer to home in the Primary Care setting
- The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, leveling health inequalities within the PCN.
Anticipated Benefits for Collaborative Working Partner:
- Increased proportion of ASCVD patients reviewed by primary care
- Increased proportion of ASCVD patients receiving expert and timely review closer to home
- Reduction in ASCVD referral rates to secondary care
- Increased proportion of patients receiving guideline-directed pharmacotherapy
- Insight into benefits of primary care pharmacist led lipid management clinics in primary care
- Support aligned to NHS Long Term Plan and CVDPREVENT
Anticipated Benefits for Novartis:
- Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine, where appropriate
- Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation
Start Date & Duration: November 2024 – 15 months
FA-11309266